Defending Covaxin, the Bhart Biotech Chairman said that his company has tremendous experience in developing vaccines; more than 70 articles on data related to Covaxin have been published in various journals

Six hospitals in England will administer the first of around 530,000 doses Britain has ready

COVID-19 vaccine: The ministry added that the doctor has a history of allergic reactions and said that there is no evidence from clinical trials that anyone has developed an inflammation of the brain after the vaccine's application

Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally

Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation

The expert committee on COVID-19 analysed the additional data and information that it had asked from SII and Bharat Biotech earlier this month

As per the report, Matthew's condition has improved since his symptoms peaked on Christmas Day but still feels fatigued

This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use

Oxford-AstraZeneca vaccine approved: The world's largest vaccine maker by volume, Serum Institute has already manufactured 50 million doses of Oxford-AstraZeneca vaccine on at-risk funding; the vaccine is cheap and easy to produce

Serum Institute of India (SII) CEO Adar Poonawalla said on December 28, that the vaccine is likely to get an emergency-use licence from the UK Medicines and Healthcare products Regulatory Agency as well as the Indian regulator, Drugs Controller General of India (DCGI), by early January

Poonawalla says Covishield shows efficacy level of 95 per cent provided two shots are taken after a gap of 2-3 months; AstraZeneca will make that public with documentation soon, he adds

The chief executive of Serum Institute - the biggest vaccine maker in the world by volume - said all trial data for Covishield has been provided to authorities in the UK and India as \"nobody wants to risk safety\"

The Oxford vaccine, which also has a tie-up with the Serum Institute of India, is expected to win approval in the UK before Thursday, speeding up the provision of the jab to the most vulnerable groups

Dalal Street witnessed gut-churning fluctuations, with the BSE Sensex swinging between historic losses and eye-popping gains, sometimes in the same session

Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine

Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency

The SII CEO says considering the high demand for vaccines in the wake of coronavirus, the next decade could be a \"golden one\" for the entire vaccine industry

Coronavirus vaccine trials: Earlier officials had said that people are unwilling to participate in the exercise thinking why take part in the trials when the vaccine would soon be available for everybody

India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm

World's biggest vaccine maker has already manufactured over 50 million doses; further production will start as soon as it gets necessary approvals in India and the UK. SII is hoping to supply 3 billion doses of vaccine in 2021